Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064 through structure-based drug design

ACS Medicinal Chemistry Letters

Volumn 4, Issue 1, 2013, Pages 91-97

  Cheng, Hengmiao ^a   Li, Chunze ^a   Bailey, Simon ^a   Baxi, Sangita M ^a   Goulet, Lance ^a   Guo, Lisa ^a   Hoffman, Jacqui ^a   Jiang, Ying ^a   Johnson, Theodore Otto ^a   Johnson, Ted W ^a   Knighton, Daniel R ^a   Li, John ^a   Liu, Kevin K C ^a   Liu, Zhengyu ^a   Marx, Matthew A ^a   Walls, Marlena ^a   Wells, Peter A ^a   Yin, Min Jean ^a   Zhu, Jinjiang ^a   Zientek, Michael ^a  

^a PFIZER INC   (United States)

Author keywords

aldehyde oxidase metabolism; antitumor; cancer; kinase inhibitor; PF 04979064; PI3K mTOR dual inhibitor

Indexed keywords

ALDEHYDE OXIDASE; CARBAZERAN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PF 04979064; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG; ZALEPLON; ZONIPORIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION;

EID: 84872359933     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300309h     Document Type: Article

References (21)

1. Eagleman, J. A.; Luo, J.; Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat. Rev. Genet. 2006, 7, 606-619
2. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K. V.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. High frequency of mutations of the PIK3CA gene in human cancers Science 2004, 304, 554
3. Shuttleworth, S. J.; Silva, F. A.; Cecil, A. R. L.; Tomassi, C. D.; Hill, T. J.; Raynaud, F. I.; Clarke, P. A.; Workman, P. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinostide 3-kinase (PI3K) inhibitors Curr. Med. Chem. 2011, 18, 2686-2714
4. Courtney, K. D.; Corcoran, R. B.; Engelman, J. A. The PI3K pathway as drug target in human cancer J. Clin. Oncol. 2008, 28, 1075-1083
5. Cheng, H.; Bagrodia, S.; Bailey, S.; Edwards, M.; Hoffman, J.; Hu, Q.; Kania, R.; Knighton, D. R.; Marx, M. A.; Ninkovic, S.; Sun, S.; Zhang, E. Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04691502 through Structure Based Drug Design MedChemCommun. 2010, 1, 139-144 Experimental procedures for in vitro biochemical assays and cellular assay were reported in this reference
6. Yuan, J.; Mehta, P. P.; Yin, M.; Sun, S.; Zou, A.; Chen, J.; Rafidi, K.; Feng, Z.; Nickel, J.; Engebetsen, J.; Hallin, J.; Blasina, A.; Zheng, E.; Nguyen, L.; Sun, M.; Vogt, P. K.; McHarg, A.; Cheng, H.; Christensen, J. G.; Kan, J. L. C.; Bagrodia, S. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity Mol. Cancer Ther. 2011, 10, 2189-2199 Experimental procedures for the TGI study were reported in this reference
7. Venkatesan, A. M.; Dehnhardt, C. M.; Delos Santos, E. Bis morpholino 1,3,5-triazine derivatives: potent, ATP-competitive phosphatidylinositol-3- kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) inhibitors: discovery of PKI-587 a highly efficacious Dual Inhibitor J. Med. Chem. 2010, 53, 2636-2645
8. Cheng, H.; Bagrodia, S.; Bailey, S. Discovery of the potent PI3K/mTOR dual inhibitor PF-04979064. Oral presentation, MEDI-493, 240th ACS National Meeting, Boston, MA, United States, August 22-26, 2010.
9. Cheng, H.; Bailey, S.; Baxi, S. M. Structure-based drug design of PI3K/mTOR dual inhibitors and PI3K selective inhibitor from tricyclic imidazo[1,5]naphthyridine series. Poster presentation, 2011 AACR Special Conferences, Targeting PI3K/mTOR Signaling in Cancer, San Francisco, CA, United States, February 24-27, 2011.
10. Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual PI3K/mTor inhibitor with potent in vivo antitumour activity Mol. Cancer Ther. 2008, 7, 1851-1863 The crystal structure of NVP-BEZ235 in PI3Kγ published in this paper was used as a reference for the initial docking studies for compound 1, using the Pfizer in-house 3D Molecular Visualization and Drug Design Tool
11. Cheng, H.; Johnson, T. W.; Hoffman, J. E.; Guo, L. C.; Liu, Z.; Johnson, T. O.; Liu, K. K. Preparation of imidazonaphthyridine derivatives for the use as PI3Kα inhibitors or PI3Kα/mTOR dual inhibitors, WO 2010038165 A1. Experimental procedures and NMR and MS data for all of the compounds discussed in this manuscript are included in the patent.
12. Edwards, M. P. Integration of Structure-based Drug Design and Physical Properties-based Optimization to Produce Cancer Clinical Candidates, 2010, AACR invited oral presentation, Washington, DC.
13. Obah, R. S. Potent inhibition of human liver aldehyde oxidase by raloxifen Drug Metab. Dispos. 2004, 32, 89-97
14. Garattini, E.; Terao, M. Increasing recognition of importance of aldehyde oxidase in drug development and discovery Drug Metab. Rev. 2011, 43, 374-386
15. Zientek, M.; Jiang, Y.; Youdim, K.; Obach, R. S. Drug Metab. Dispos. 2010, 38, 1322-1327 The experimental procedure for the human liver S9 assay was reported in this paper
16. Pryde, D. C.; Tran, T.; Jones, P.; Duckworth, J.; Howard, M.; Gardner, I.; Hyland, R.; Webster, R.; Wenham, T.; Bagal, S.; Omoto, K.; Schneider, R. P.; Lin, J. Medicinal chemistry approaches to avoid aldehyde oxidase metabolism Bioorg. Med. Chem. Lett. 2012, 22, 2856-2860
17. Hutzler, M.; Yang, Y.; Albaugh, D.; Fullenwider, C. L.; Schmenk, J.; Fisher, M. B. Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocyte Drug Metab. Dispos. 2012, 40, 1322-1327
18. Akabane, T.; Gerst, N.; Masters, J. N.; Tamura, K. A quantitative approach to hepatic clearance prediction of metabolism by aldehyde oxidase using custome pooled hepatocytes Xenobiotics 2012, 42, 863-871
19. Kaye, B.; Offerman, J. L.; Reid, J. L.; Elliott, H. L.; Hillis, W. S. A species difference in the presystemic metabolism of carbazeran in dog and man Xenobiotica 1984, 14, 935-945
20. Dalvie., D.; Zhang, C.; Chen, W.; Smolarek, T.; Obach, R. S.; Loi, C. M. Cross-species comparison of the metabolism and excretion of zoniporide: Contribution of aldehyde oxidase to interspecies differences Drug Metab. Dispos. 2010, 38, 641-654
21. Rosen, A. S.; Fournie, P.; Darwish, M.; Danjou, P.; Troy, S. M. Zaleplon pharmacokinetics and absolute bioavailability Biopharm Drug Dispos. 1999, 20, 171-175